Celsus Therapeutics PLC (ADR)(NASDAQ:CLTX) an emerging growth, development-stage biopharmaceutical organization, declares that Gur Roshwalb, MD, chief executive officer, is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference at Crowne Plaza Hotel in New York City. Dr. Roshwalb will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.
·
Event: Oppenheimer
25th Annual Healthcare Conference
·
Date: Wednesday,
December 10, 2014
·
Time: 4:30
p.m. Eastern Time
Celsus
Therapeutics PLC (ADR)(NASDAQ:CLTX)
opened the session at $5.25, trading in a range of $ 5.25- 5.89, and was at
$5.73. The stock showed a positive performance of +10.19% in the recent trading
session. The stock was trading on a volume of 19,339.00 shares and the average
volume of the stock remained 4,062.00 shares.
Sypris Technologies, Inc. (Sypris) a subsidiary of Sypris Solutions, Inc (NASDAQ:SYPR)
recently declared that it has joined
into a contract to extend and expand its long-term supply relationship with
Meritor to provide drivetrain components for its drive axle and trailer axle
assembly operations in North America. The arrangement extends two existing
supply contracts, as well as adds new products and services.
Sypris
Solutions, Inc (NASDAQ:SYPR)
at recent check, traded 14,777.00 shares
in the recent trading session and the average volume of the stock remained 28,620.00
shares. The 52 week range of the stock remained $2.51- $6.50. The stock showed
a positive movement of 3.32% and was
recently trading at $2.80. The market capitalization of the stock remained 56.49
Million.
China
Telecom Corporation Limited (ADR) (NYSE:CHA) declared
that both its website and online annual report were accredited platinum awards
in 2014 Spotlight Awards Global Communications Competition by League of
American Communications Professionals LLC (LACP). In addition, the organization's
annual report (in print) won gold award in 2014 International ARC Awards.
China
Telecom Corporation Limited (ADR) (NYSE:CHA)
reported 17,167.00 shares has been exchanged so far while the average volume is
about 42,293.00 shares. The stock gained 5.73% and most recently was trading at
$61.06. The beta of the stock is
recorded at 0.38 and the EPS of the stock remained 3.58. The shares outstanding
of the stock are 13.88 billion.
Lpath,
Inc.(NASDAQ:LPTN) declared that in
consultation with Pfizer Inc., Lpath has finished enrollment of its clinical
trial evaluating iSONEP™ in patients with wet age-related macular degeneration
(wet AMD), which is also referred to as the "Nexus" study. This
multicenter, Phase 2 clinical trial enrolled patients who have not responded
well to existing anti-vascular endothelial increase factor (VEGF) therapies
including Lucentis®, Avastin® and Eylea®.
Lpath,
Inc.(NASDAQ:LPTN) declined volume of 22,496.00
shares, while the average volume remained 30,770.00 shares. The stock gained 8.33%
to $ 2.60. The EPS of the stock over the last 12 months remained -0.76. To get
a view of its performance, the one month trend of the stock was -10.65% and the
three month trend remained negative -22.62%.
0 comments:
Post a Comment